Global Mycology Immunoassays Testing Market Size By Type (ELISA, Rapid Tests), By Application (Hospitals, Blood Banks), By Region, And Segment Forecasts, 2023 to 2032

The Global Mycology Immunoassays Testing Market was valued at USD 615 million in 2023 and is projected to surpass USD 1.18 billion by 2031, expanding at a CAGR of 8.3% during the forecast period of 2023–2031. This growth is fueled by the rising incidence of fungal infections globally, growing awareness about early diagnosis, and increasing adoption of advanced immunoassay technologies in diagnostic laboratories and hospitals. The market is witnessing strong demand for rapid, accurate, and sensitive detection methods for invasive fungal diseases (IFDs), particularly among immunocompromised patients, which is significantly boosting the adoption of mycology immunoassays.

Drivers:

1. Rising Fungal Infection Incidence:

The surge in immunocompromised populations due to cancer, HIV/AIDS, organ transplantation, and use of immunosuppressants has led to a global rise in opportunistic fungal infections, thereby increasing the need for efficient diagnostic tools like mycology immunoassays.

2. Advances in Immunodiagnostic Technologies:

Continuous improvements in enzyme-linked immunosorbent assay (ELISA), lateral flow assays, and multiplex immunoassays have enhanced the specificity, sensitivity, and turnaround time of fungal diagnostics, fostering market expansion.

3. Emphasis on Early Detection:

Healthcare providers are increasingly emphasizing early detection of invasive fungal infections to reduce morbidity and mortality. Immunoassays are preferred for their capability to identify fungal antigens or host antibodies, aiding prompt treatment decisions.

Restraints:

1. Limited Accessibility in Low-Income Regions:

The high cost of advanced immunoassay equipment and test kits, along with inadequate laboratory infrastructure in developing regions, limits the market's penetration in low-resource settings.

2. False Positives and Cross-Reactivity Issues:

Despite technological improvements, some immunoassays still present false positives or cross-reactivity with non-target pathogens, affecting diagnostic accuracy and limiting trust among clinicians.

Opportunity:

1. Expansion in Emerging Markets:

Growing investments in healthcare infrastructure, rising awareness of fungal infections, and increasing availability of diagnostic services in Asia-Pacific and Latin America present lucrative growth opportunities for market players.

2. Integration of AI and Digital Platforms:

The integration of artificial intelligence and digital diagnostic platforms with immunoassays for real-time data interpretation and remote diagnostics offers immense potential for innovation and efficiency in fungal infection diagnosis.

Market by System Type Insights:

The ELISA-based mycology immunoassays segment led the market in 2023, accounting for the highest revenue share due to its high sensitivity and widespread use in detecting fungal antigens and antibodies. The lateral flow assays segment is expected to register the highest CAGR, driven by its point-of-care usability, rapid turnaround time, and increasing use in field diagnostics.

Market by End-Use Insights:

Hospitals dominated the market in 2023 as the primary diagnostic centers for critically ill and immunocompromised patients, with clinical laboratories following closely. The reference laboratories segment is anticipated to witness robust growth owing to the rising trend of outsourcing diagnostic services for cost and quality advantages.

Market by Regional Insights:

North America held the largest share of the global mycology immunoassays testing market in 2023 due to the region's well-established healthcare infrastructure, high awareness levels, and presence of key market players. However, Asia-Pacific is projected to witness the fastest growth, supported by expanding healthcare access, rising healthcare expenditure, and increasing cases of fungal infections in countries like India and China.

Competitive Scenario:

Key players in the Global Mycology Immunoassays Testing Market include Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Meridian Bioscience, Inc., IMMY, Dynamiker Biotechnology (Tianjin) Co., Ltd., and Vircell S.L. These companies are focusing on expanding product portfolios, geographic reach, and strategic partnerships. Noteworthy developments include:

2023: Bio-Rad Laboratories launched a new multiplex ELISA kit capable of detecting multiple fungal antigens simultaneously, reducing diagnostic turnaround.

2024: Meridian Bioscience partnered with regional laboratories in Southeast Asia to enhance access to rapid mycology immunoassays in underserved markets.

2025: IMMY introduced AI-enhanced lateral flow readers for accurate detection of cryptococcal and histoplasma infections.

Scope of Work – Global Mycology Immunoassays Testing Market

Key Market Developments:

July 2023: Thermo Fisher Scientific expanded its mycology diagnostic line with an automated system compatible with hospital laboratory networks.

February 2024: Vircell S.L. launched a comprehensive immunoassay panel targeting Aspergillus and Candida infections with enhanced specificity.

May 2025: Dynamiker Biotechnology received regulatory approval for a next-generation fungal antigen detection kit in Latin America.

FAQs:

1) What is the current market size of the Global Mycology Immunoassays Testing Market?

The market size was valued at USD 615 million in 2023.

2) What is the major growth driver of the Global Mycology Immunoassays Testing Market?

The major growth driver is the rising incidence of fungal infections among immunocompromised individuals.

3) Which is the largest region during the forecast period in the Global Mycology Immunoassays Testing Market?

North America held the largest market share in 2023.

4) Which segment accounted for the largest market share in the Global Mycology Immunoassays Testing Market?

The ELISA-based immunoassays segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Mycology Immunoassays Testing Market?

Key players include Bio-Rad Laboratories, Thermo Fisher Scientific, Meridian Bioscience, IMMY, and Vircell S.L.